These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 6291792)

  • 1. Bacteriological comparison of the activities of ceftriaxone, a new long-acting cephalosporin, with those of other new cephalosporins.
    Arisawa M; Ohshima J; Ohsawa E; Maruyama HB; Sekine Y; Mitsuhashi S
    Chem Pharm Bull (Tokyo); 1982 Jul; 30(7):2544-54. PubMed ID: 6291792
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparative study of ceftriaxone, cefotaxime and moxalactam against 150 Gram negative strains (author's transl)].
    Nasnas R; Gutmann L; Kitzis MD; Goldstein F; Acar JF
    Pathol Biol (Paris); 1982 Jun; 30(6):341-4. PubMed ID: 6287385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of ceftazidime and ceftriaxone.
    Keenholtz SL; Jacobus NV; Tally FP; Gorbach SL
    Clin Ther; 1983; 5(6):603-16. PubMed ID: 6313195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of antimicrobial activity and stability to beta-lactamases of cefoperazone, cefotaxime, lamoxactam and ceftriaxon].
    Baumgärtner M; Grehn M; Wundt W
    Zentralbl Bakteriol Mikrobiol Hyg A Med Mikrobiol Infekt Parasitol; 1982 Jun; 252(2):208-21. PubMed ID: 6289564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ceftriaxone - a new broad-spectrum semisynthetic cephalosporin. In vitro activity against gram-negative bacilli sensitive and resistant to gentamicin.
    Bremner DA
    Chemotherapy; 1983; 29(4):283-8. PubMed ID: 6307605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [In vitro antibacterial activity of a new cephalosporin: cefpirome (HR 810). Comparison with ceftriaxone, cefotaxime, latamoxef and ceftazidime].
    Le Noc P; Bryskier A; Le Noc D
    Pathol Biol (Paris); 1986 Jun; 34(5 Pt 2):567-71. PubMed ID: 3534744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro activities of cefmenoxime (SCE-1365) and newer cephalosporin derivatives of clinical utility.
    Ahonkhai VI; Cherubin CE; Shulman MA; Bancroft U
    Antimicrob Agents Chemother; 1982 Jun; 21(6):999-1002. PubMed ID: 6287933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergism and antagonism of ceftizoxime and other new cephalosporins.
    Moellering RC; Willey S; Eliopoulos GM
    J Antimicrob Chemother; 1982 Nov; 10 Suppl C():69-79. PubMed ID: 6296032
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of susceptibilities of anaerobic bacteria to cefmenoxime, ceftriaxone, and other antimicrobial compounds.
    Pollock HM; Holt J; Murray C
    Antimicrob Agents Chemother; 1983 May; 23(5):780-3. PubMed ID: 6307137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of the new cephalosporin antibiotics cefotaxime, cefoperazone and lamoxactam].
    Pulverer G; Peters G
    Med Welt; 1982 Apr; 33(17):642-4. PubMed ID: 6285119
    [No Abstract]   [Full Text] [Related]  

  • 11. Cefodizime: effects of sub-inhibitory concentrations on adhesiveness and bacterial morphology of Staphylococcus aureus and Escherichia coli: comparison with cefotaxime and ceftriaxone.
    Braga PC; Dal Sasso M; Maci S
    J Antimicrob Chemother; 1997 Jan; 39(1):79-84. PubMed ID: 9044031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative bacteriostatic and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato.
    Murgia R; Marchetti F; Cinco M
    Antimicrob Agents Chemother; 1999 Dec; 43(12):3030-2. PubMed ID: 10582905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cefotaxime, moxalactam and ceftriaxone: comparison of in vitro activity against hospital strains of Enterobacteriaceae belonging to the 4 principal phenotypes of sensitivity to beta-lactams].
    Jarlier V; Bismuth R; Grosset J
    Pathol Biol (Paris); 1983 May; 31(5):336-42. PubMed ID: 6312393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of complicated urinary tract infections with the long acting cephalosporin, ceftriaxone.
    Rothwell DL; Bremner DA; Taylor KM
    N Z Med J; 1983 May; 96(732):392-4. PubMed ID: 6302612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibacterial properties of Ro 13-99041, a long-acting new cephalosporin.
    Angehrn P; Probst PJ
    Chemotherapy; 1981; 27 Suppl 1():9-14. PubMed ID: 7249797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-kill studies of antimicrobial combinations including cefotaxime, ceftriaxone, vancomycin and meropenem against cephalosporin-resistant Streptococcus pneumoniae.
    Kim BN; Woo JH; Kim YS; Ryu J; Kim MN; Pai CH
    Chemotherapy; 2000; 46(5):303-8. PubMed ID: 10965094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro and in-vivo efficacy of ceftriaxone, moxalactam, and chloramphenicol against Haemophilus influenzae type b.
    Connor E; Melick C; Yogev R
    J Antimicrob Chemother; 1982 Dec; 10(6):517-25. PubMed ID: 6298172
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative in vitro activity of cefodizime and other antibiotics against pathogens recently isolated in Italy.
    Nicoletti G; Blandino G; Cocuzza G; Dainelli B; Maida A; Debbia E; Schito G
    Chemotherapy; 1996; 42(2):100-6. PubMed ID: 8697884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of ceftriaxone against clinical bacterial isolates in Nigeria.
    Obaseiki-Ebor EE; Afonya TC; Oyaide SM
    Chemotherapy; 1985; 31(2):130-7. PubMed ID: 3872779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftriaxone: a long-acting cephalosporin.
    Am J Med; 1984 Oct; 77(4C):1-118. PubMed ID: 6093510
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.